Collegium Pharmaceutical, Inc (COLL) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Collegium Pharmaceutical reported revenue of $780.6M, up 23.6% from $631.4M the year before. Net income was $62.9M (a 8.1% net margin), or $1.73 per diluted share. Gross margin was 59.3% and operating margin was 23.0%. Operating activities generated $329.3M of cash, leaving $327.6M of free cash flow. At fiscal year end, Collegium Pharmaceutical held $1.66B in total assets against $1.36B in total liabilities, including $231.3M of cash and equivalents.
Open the full interactive Collegium Pharmaceutical financials → Quarterly statements, key ratios, valuation history and price charts.
Collegium Pharmaceutical Key Stats
| Share Price | $21.53 |
|---|---|
| Market Cap | $698.9M |
| P/E Ratio | 12.4 |
| Revenue YoY Growth | +23.6% |
| 52-Week Range | $21.53 – $49.84 |
| Shares Outstanding | 32.5 million (basic, 2026 Q2) |
Collegium Pharmaceutical Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $310.0M | $276.9M | $463.9M | $566.8M | $631.4M | $780.6M |
| Cost of Goods Sold | $130.2M | $126.3M | $254.4M | $240.6M | $254.1M | $317.3M |
| Gross Profit | $179.8M | $150.6M | $209.5M | $326.2M | $377.3M | $463.3M |
| Operating Income | $56.2M | $17.6M | $33.3M | $167.0M | $169.9M | $179.6M |
| Pre-Tax Income | $27.6M | -$3.4M | -$28.8M | $75.7M | $98.6M | $92.6M |
| Income Tax | $830,000 | -$74.9M | -$3.8M | $27.6M | $29.4M | $29.7M |
| Net Income | $26.8M | $71.5M | -$25.0M | $48.2M | $69.2M | $62.9M |
| Diluted EPS | $0.76 | $1.86 | -$0.74 | $1.29 | $1.86 | $1.73 |
Collegium Pharmaceutical Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $209.4M | $205.4M | $193.5M | $199.9M |
| Net Income | $31.5M | $17.0M | $14.5M | -$15.1M |
| Diluted EPS | $0.84 | $0.43 | $0.40 | -$0.46 |
Collegium Pharmaceutical Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $174.1M | $186.4M | $173.7M | $238.9M | $70.6M | $231.3M |
| Current Assets | $277.9M | $315.5M | $420.0M | $537.6M | $482.3M | $691.4M |
| Total Assets | $643.8M | $692.1M | $1.17B | $1.14B | $1.66B | $1.66B |
| Current Liabilities | $239.5M | $279.6M | $433.7M | $457.9M | $509.5M | $440.0M |
| Total Long-Term Debt | $257.1M | $250.0M | $701.0M | $667.2M | $852.5M | $809.3M |
| Total Liabilities | $457.8M | $489.1M | $979.3M | $947.9M | $1.43B | $1.36B |
| Shareholders' Equity | $186.0M | $202.9M | $194.8M | $195.4M | $228.8M | $301.7M |
Collegium Pharmaceutical Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $93.9M | $103.6M | $124.2M | $274.7M | $205.0M | $329.3M |
| Cash From Investing | -$373.8M | -$1.9M | -$573.7M | -$70.8M | -$287.8M | -$63.5M |
| Cash From Financing | $286.5M | -$89.3M | $436.7M | -$140.2M | -$60.6M | -$110.2M |
| Free Cash Flow | $88.4M | $101.6M | $122.6M | $274.3M | $203.3M | $327.6M |
Figures from Collegium Pharmaceutical's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Collegium Pharmaceutical financials page for every line item.
Collegium Pharmaceutical Company Profile
| Ticker | COLL |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Stoughton, Massachusetts |
| Incorporated in | Virginia |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001267565 |
Frequently Asked Questions
What was Collegium Pharmaceutical's revenue in fiscal 2025?
Collegium Pharmaceutical (COLL) reported revenue of $780.6M for fiscal 2025.
What is Collegium Pharmaceutical's annual revenue history?
Collegium Pharmaceutical's annual revenue by fiscal year: 2020: $310.0M; 2021: $276.9M; 2022: $463.9M; 2023: $566.8M; 2024: $631.4M; 2025: $780.6M.
What was Collegium Pharmaceutical's net income in fiscal 2025?
Collegium Pharmaceutical reported net income of $62.9M for fiscal 2025.
What was Collegium Pharmaceutical's earnings per share (EPS) in fiscal 2025?
Collegium Pharmaceutical's diluted EPS was $1.73 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Collegium Pharmaceutical generate in fiscal 2025?
Collegium Pharmaceutical generated $327.6M of free cash flow in fiscal 2025.
What was Collegium Pharmaceutical's revenue last quarter?
In its most recent reported quarter (2026 Q2), Collegium Pharmaceutical reported revenue of $199.9M.
How much debt does Collegium Pharmaceutical have?
Collegium Pharmaceutical reported $809.3M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Collegium Pharmaceutical are outstanding?
Collegium Pharmaceutical reported a weighted average of 32.5 million basic shares outstanding in 2026 Q2.
What is Collegium Pharmaceutical's market cap?
Based on its latest closing price, Collegium Pharmaceutical (COLL) has a market capitalization of about $698.9M.
When does Collegium Pharmaceutical's fiscal year end?
Collegium Pharmaceutical's fiscal year end, as registered with the SEC, is December 31.
Where is Collegium Pharmaceutical headquartered?
Collegium Pharmaceutical lists its business address in Stoughton, Massachusetts in its SEC filings.